

- Speaker 1: [00:04](#) Welcome to The Bill Walton Show, featuring conversations with leaders, entrepreneurs, artists and thinkers, fresh perspectives on money, culture, politics, and human flourishing. Interesting people. Interesting things.
- Bill Walton: [00:25](#) Welcome to The Bill Walton Show. Today, as you can see, we're joining you via our library and we're going to be having our guests join via Zoom. And it's an evolving technology and we think we've got it mostly mastered, but there's some connection issues, and so if we fade in or out, just bear with us. The content is outstanding and worth any technical difficulties we may have. Today, we want to talk with Rosemary Gibson and Frank Gaffney. And Rosemary is the author of *China Rx: Exposing the Risks of America's Dependence on China for Medicine* and many other books that put a human face on our healthcare issues. She's a senior advisor at the Hastings Center. And at the Robert Wood Johnson Foundation, she's successfully established palliative care in more than 1,600 hospitals in the United States. She has a Lifetime Achievement Award from the American Academy of Hospice and Palliative Medicine. Rosemary, welcome.
- Rosemary Gibson: [01:27](#) Thank you, Bill. It's a pleasure to be with you.
- Bill Walton: [01:29](#) I'm thrilled you're here. Also joining me as my frequent collaborator and good friend, Frank Gaffney. Frank is the founder of the Center for Security Policy and vice chairman of the Committee for the Present Danger: China. To kick today's show off I want to talk about where we are with our supply chain issues. We're dealing with a global pandemic and we're concerned about healthcare equipment, supplies, drugs, that sort of thing. But this has been a problem in the works for years.
- Bill Walton: [02:04](#) And Clyde Prestowitz, who was one of our trade representatives during the Clinton era has written recently, I think yesterday. He says, "In addition to making the world sick, the coronavirus pandemic has dramatically illustrated the high cost of global supply chain. For 40 years, economists have promoted globalization based on supply chains that rely heavily on cheap, nonunion Chinese labor to assemble parts around the world that are made into final products and then reshape largely to consumers in rich countries. This was said to be an ideal division of labor that optimize returns to all participants." Well, we need to dig into this because that certainly is not turned out to be the case and we're reaping the rewards or so-called of that strategy. Diana, would you talk a bit, start kicking off a bit about our

medical healthcare supply chain issues and where we stand.  
Diana, Rosemary.

Rosemary Gibson: [03:08](#) Yeah. Thank you, Bill. You mentioned the quote from what went on back in the early 1980s when we opened up free trade with China. It's quite remarkable that when I was writing the China Rx book, I was sitting in the same room where I am now and I put the pieces together that within a couple of years, two years of opening up free trade with China, that's when we lost our last aspirin plant. We cannot make aspirin in the United States because China's companies formed a cartel, dumped it on the global market, and drove out all the producers. So we can't make the core chemicals in our aspirin. It's when we lost our last penicillin plant and it's the same playbook. This isn't just because China's cheaper. It's not because of weaker regulations, but there's a cartel formation that is illegal under US law, but no one ever took Chinese companies to task for violating US antitrust law.

Bill Walton: [04:17](#) So, when did this begin?

Rosemary Gibson: [04:20](#) It began in 1984 the US Congress and the White House agreed on, "Let's have generic drugs," and generic drugs are now 90% of the medicines that we all take. And it was considered a boon back then because it would be cheaper. These would be products that were branded products and their patents had run out and why don't we make them available to people at lower cost? And all of us I'm sure have benefited or we know people who've benefited to having access to cheaper drugs.

Bill Walton: [04:56](#) Well, now almost 90% of our drugs are generic.

Rosemary Gibson: [04:58](#) That's right. And where I've come out is thousands and thousands of the core chemicals and ingredients to make them, Bill, we depend on China. And the pandemic, how you opened the story up, here we are in the middle of a global pandemic and let's take the medicines that would be needed right today in hospitals for people being treated with severe cases. So, people will need sedatives if they have to be on a ventilator, they might need antibiotics if they get a bacterial infection, they might need epinephrine or dopamine to raise their blood pressure if they're collapsing. These are the bread and butter medicines in our medicine cabinets and hospitals. These aren't those shiny or the brand new drugs. These are the basic bread and butter ones that have been around for years. To make them, China controls 90% of the core chemicals. So, here we have a situation where you have a global pandemic and the

whole world depends on a single country for those core chemicals to make critical drugs. And this was regrettably predicted in China Rx when it came out in 2008

Bill Walton: [06:17](#) Yeah, China Rx, you wrote two years ago is an incredible story. I recommend everybody to buy it, read it, study it, and talk to your elected officials about doing something about it.

Bill Walton: [06:29](#) Frank, the Chinese have been at this for a while, not just with medicine but with other strategic supplies and goods. What's your sense of how this got started? Was it the free trade agreement that basically changed the arrangements?

Frank Gaffney: [06:48](#) Well, I'd go back to the early 1990s when then General Secretary of the Chinese Communist Party, Deng Xiaoping observed that the Cold War between the United States and the Soviet Union was over and that the Soviets, of course, had lost. And then he said, and this was to trusted party cadre colleagues, there is now going to be a new cold war between the United States and China, and China will win this one. And I think from that moment forward with the enunciation of what came to be known as his hide and bide strategy for achieving the kind of integration that Rosemary has just talked about, the kind of dominance economically in so many production areas. This one is particularly resonant because especially in the midst of a pandemic crisis, suddenly the warnings that Rosemary was sounding to her great credit two years ago are very much top of mind for all of us.

Frank Gaffney: [08:05](#) The other piece of this though, Bill, that I think is operating is this is personal to virtually all of us. This is not something that is an abstraction like any of the other things that you mentioned we could talk about, flat screens, rare earth minerals, steel, you name it. There are industries that have electronics chips and so on that had been taken down by exactly the same predatory trade practices that Rosemary has documented in China Rx in this particular microcosmic example. And it's part of that strategy, hiding the true intentions of the Chinese over all these years, biding their time, but inexorably strangling the industrial capabilities of the United States, and Rosemary says, the free market itself. That's what's going on here and I think this is the moment when it must not be allowed to persist either with respect to medicines or any of these other critical national security as well as economic security interests.

Bill Walton: [09:15](#) Well, from America's standpoint, I think we did this largely with good intentions. The idea was that we would bring China into

the free trade system and they would trade with us. They'd become wealthier, as they became wealthier they'd become more democratic and integrate into the end of the world economic, political, social order. That hasn't happened. But we didn't reckon with was how powerful the Chinese Communist Party is in China. And in many ways we're not talking about the Chinese, we're talking about the Chinese Communist Party and its strategy.

Frank Gaffney: [09:47](#) We also didn't reckon on is that they had no interest in actually just being another nation in the great international community. They wanted to be, they've set their sights on becoming, and they are well on their way towards actually achieving their goal of world domination.

Bill Walton: [10:05](#) Well, Rosemary, I was reading your book getting increasingly disturbed and then I came upon a drug that I now take, which is called, and I can't pronounce it, amlodipine besylate or something like that and it's a generic. But then you point out 89% of our prescriptions filled in the United States are generic.

Rosemary Gibson: [10:31](#) That's right. And China already has 10% market share. They make 10% of our generic drugs right now. And that happened in just a very short period of time. The first generic approved from China was in 2007 and they are ramping up very quickly now. And meanwhile, here in the US, our generic manufacturing base is almost collapsed. And meanwhile our taxpayer dollars, the money we pay when we buy our prescription drugs, \$6 billion a year is going to build up China's industry as our industry here is falling apart.

Rosemary Gibson: [11:11](#) Back to the geopolitical perspective here, Bill, if you think about it if you control medicines and among those you control antibiotics, you control the world. We're concerned about a virus, it's infectious. But bear in mind if there were a bacterial infection, we can't make antibiotics here in the United States anymore.

Bill Walton: [11:37](#) Wasn't it one of the big issues that we don't know where, it's not just China, but it's the manufacturing plants in China. And if drugs are manufactured here in the United States, we have FDA inspectors that go in and make sure the facility is what we want it to be, yet we've got no ability to inspect the facilities in China, and the Chinese Communist Party sort of routinely doesn't let us do that

Rosemary Gibson: [12:09](#) Right now, there are no FDA inspectors in China because as federal employees they were pulled back, which is the wise thing to do given we want to protect their health and safety. But China has made it very difficult for the federal government to ensure the safety of products made in China. Think about this, you are a federal employee and you have a lot of great technical knowledge on how to make medicines, and you go into a plant there and you write up a report that says, here are all these deficiencies. You're the person that's stopping potentially a very large Chinese company from sending product to the United States. Do you think the Chinese government would ever want to give you a visa again to come back?

Rosemary Gibson: [12:58](#) And what I'm very concerned about, Bill, is that where are we headed? I think we're coming to the point very quickly where China's going to say to the US, "We don't need you anymore. We don't want you anymore to come in and inspect, let alone our food that comes from China, but our medicines because we'll do it ourselves." We have our own China FDA and the US taxpayers have helped grow the sophistication of the China FDA, but it has a long way to go.

Rosemary Gibson: [13:33](#) Two years ago there was a blood pressure medicine that was sold to millions of Americans and people around the world that had carcinogens in it and the Chinese product had more than 200 times the acceptable limit per pill. And so China's view is, and I write about this in China Rx, if the attitude is one of the reasons our products are so cheap is because we assume no liability for them. And once you become dependent on a single country, it's take it or leave it because you have no choice. And we've done that. We have already started to do this, Bill. That in the United States of America our federal agency is in a position of having to balance out having some supply versus having some substandard products on the market.

Rosemary Gibson: [14:27](#) There was one plant in China, to show how concentrated we are, we wouldn't do this for oil, we wouldn't have 80% or 90% of the world's oil supply in a single country and the refining capacity. There was one plant in China that blew up and there was a global shortage of a very important antibiotic to treat sepsis. And the regulators in Europe said, "We're going to allow this come into Europe." And the FDA did too. But the Europeans said, "It doesn't meet standard, but because we have no choice." So globalization has been a form of de facto deregulation and a diminution in the standards that Americans have come to expect. After all these generations of building up the gold standard, it's just being totally watered down.

Rosemary Gibson: [15:11](#) And in this case, Bill, obviously, you're talking about life and death. When those standards are lowered, it can be fatal. And Rosemary's chronicled some examples where that's actually happened to Americans. But could I just come back to something she touched on a moment ago, particularly given your background in finance, we have been enabling this, not just our companies that have been looking for the lowest labor costs that can allow them to eke out some marginal advantage, some profit, I'm talking about Wall Street.

Rosemary Gibson: [15:45](#) You mentioned \$6 billion, Rosemary, that's obviously a huge number, but it's a tiny fraction of what American capitalists have been sending in the way of stocks and bonds investments to China. By some estimates, it's \$3 trillion all-in. And they're coming back, we're told, for three to \$5 trillion more. If that money isn't made available to the Chinese Communist Party and that's effectively who we're subsidizing here, we're going to be able to deny them the money to do some of the things that Rosemary's chronicled, as I said. But also, a whole host of other things that involve among other things, building weapon systems with which to kill us. This is truly insane.

Bill Walton: [16:35](#) Well, we did have something back in the '80s or '90s called the China lobby. And, as you recollect, we had Henry Kissinger, and Alexander Haig, and Cyrus Vance. They were in the lead of that. Goldman Sachs was a major player.

Rosemary Gibson: [16:51](#) Still is.

Bill Walton: [16:51](#) Well, maybe still are. The unintended consequences or maybe intended, I don't know how to call it, are that you pass something called the US-China Trade Relations Act of 2000, and we signed it in law because we felt like that was going to bring China into the world order. We also thought letting low-value manufacturing go to China with lower costs for American consumers. And initially, that was the effect. And yet the first year, what was it, three years after the law was signed, we ended up with a trade deficit of \$114 billion. I'm quoting Rosemary on that. And so we've been living with that deficit ever since. But the thing that I'm interested in when I read your book, Rosemary, is that it's not just low-value manufacturing jobs that got outsourced, but when you came around to the pharmaceutical industries, the big pharmaceutical companies have been sending their research and development labs to China. And I think Merck is now, what was it, a year and a half ago, two years ago, they opened 1.5 billion research facility in Beijing. Thoughts?

Rosemary Gibson: [18:15](#) You're right. China is ramping up quickly from making the chemicals, to the finished drugs, to doing the R&D. And to their credit, they want to have medicine for their one point-something billion people. But our US-based headquarter companies are investing billions of dollars in research capability in China as we have lost tens and thousands, probably hundreds of thousands of STEM jobs, of jobs that are the future of our country. And this is part of China's plan to address and go after, and take over, disrupt, dominate, and displays 20 different sectors of our economy that are the future. Without that, we have no economy. We'll be flipping burgers, and maybe getting tourists, and doing health care, home care aides, and doctors, and nurses. We'll have nothing left. So, you're right. And those finished drug, you can bet those R&D for those drugs, they're going to be made in China and then sent back here.

Frank Gaffney: [19:26](#) If they choose.

Rosemary Gibson: [19:28](#) If they choose to, yes.

Frank Gaffney: [19:31](#) And, as [inaudible 00:19:31] pointed out that maybe they won't. In fact, we've seen in this present crisis that they haven't been so much. And that's aside from the problem of the adulteration of the drugs, making them actually toxic in some cases. What if they just cut us off because they say they don't need us anymore or they don't have enough for their own people? That's a distinct possibility. And I just want to say again, Bill, hats off to Rosemary for having warned about this two years ago and she was picking up on inaction by successive administration. So it's not uniquely the fault of the present one. In fact, I think the present one is doing more than anybody else, particularly in this crisis to try to remedy it. But it's part of an overall failure of understanding the true nature of the Chinese Communist Party, its actual ambitions, and their implications for the rest of us.

Rosemary Gibson: [20:27](#) And I'm sure you may have seen the statement from the Chinese government media actually threatening to withhold drugs and to throw the United States into the ocean of or hell of coronavirus. And there were threats before, but this the most brazen.

Bill Walton: [20:48](#) So you testified in front of Congress in July of 2019, so what is that, 10 months ago. What happened after that? Was there any action among either the Senate or the House based on what they learned from you and the other testimony?



- Rosemary Gibson: [21:07](#) Yeah. That was testimony before the US-China Economic and Security Review Commission. That was combined with a representative from the Department of Defense and others and it was very, very powerful. And frankly, just one other point on the quality issue, one of the retired military people who's a commissioner on the US-China Commission spoke up and said, and I have the 90-second clip, I wish you could show it. He said, "I got three different blood pressure medicines and they were contaminated with rocket fuel ingredients made in China." He said, "If I'm getting that, then active duty military must also be getting it."
- Bill Walton: [21:45](#) Well, send us the clip and we'll make sure if you've got access to it, we'll fit it in.
- Rosemary Gibson: [21:54](#) That's great.
- Frank Gaffney: [21:55](#) This raises the point that it's a national security problem.
- Rosemary Gibson: [21:58](#) Absolutely.
- Frank Gaffney: [21:59](#) Not just a public health one.
- Rosemary Gibson: [22:02](#) And then that migrated to a testimony before the House Energy and Commerce Health Subcommittee where there was dramatic interest in Made in America, and then most recently with the Senate Small Business Committee chaired by Senator Rubio.
- Rosemary Gibson: [22:19](#) Now, small businesses here in the United States, unlike the multinationals are ready to go and they want to make product, the critical drugs that we need here in the United States. They want to use innovative technology. These are the new innovators. And we've got to allow them room in this marketplace to be able to make it and to sell their product. And we if we brought ... We could actually ... We're getting into solutions here, but just to preview, we can actually make generic drugs here in the United States faster, cheaper, with a much smaller environmental footprint, and real-time quality control.
- Frank Gaffney: [22:57](#) Real-time quality control is the key point.
- Rosemary Gibson: [23:00](#) So it has percolated up and I've been impressed with how much talk now there is about our dependence on China for medicine. If nothing else, China Rx has started that and now we have to get to solutions, which again, we could have a whole nother show on that.



- Bill Walton: [23:16](#) Well, let's have another show on detailed solutions. But let's sort of frame that because this pandemic, this virus has been horrific, but there are silver linings to this. And what it's done is it exposed our tremendous vulnerability to China and not just with medical supplies but with everything else. And how they behaved, you mentioned something, they said they're threatening to cut people off, is that a random government official or is that something that's looming and something the Chinese are thinking is a strategic piece of aggression?
- Rosemary Gibson: [23:56](#) Oh, I think it was a very strategic and very clear statement in the state news agency, so this is not random. It's not a professor at a university. Everything is said with a purpose. I hope that is a wake-up call. I hope it is a silver lining. And, there are so many good people who've been working on the challenges of our dependence on China for so many things. This topic of medicine, which everybody can identify with, as Frank said earlier, it's personal. You give it to your kids, you rely on it when you go into a hospital.
- Rosemary Gibson: [24:30](#) And I've had doctors tell me that they are losing trust in the generic drugs, some of them that they're giving to their patients. I don't want to scare people, but some of them say, "I see these medicines and they don't seem to be working as they should". So this is a gateway for the public to understand what's really going on with China and the fact that you want to withhold medicines from people and send them contaminated product. The narrative is there. So I hope it is a way and a means of waking up our country to have solutions and not go back to the way six months from now we were doing things,
- Bill Walton: [25:09](#) Well, my understanding is that the White House does have this on the radar screen for when things calm down that we can start putting a new regime in place. Frank, have you heard anything?
- Frank Gaffney: [25:21](#) I've heard that too. My only concern is, Bill, who knows when things are going to start calming down.
- Bill Walton: [25:28](#) True.
- Frank Gaffney: [25:28](#) And I think Peter Navarro, for example, with whom Rosemary has worked is clear-eyed about this. He's talking about it. I think he's helping prepare this executive order that is clearly something needed right now. And I believe he understands that whatever we wind up doing after things calm down, as they say, we had best be getting our ducks in a line right now to try to

diversify our sources of supply, to assure that we have quality control in place, and to minimize both in this particular space, but also more generally our dependence upon Communist China for anything that matters to us

Bill Walton: [26:23](#) Well, I want to call an audible and say let's talk right now about what we ought to be doing. Because I think we've given ourselves a sense that we've got a big problem. Rosemary, what do you recommend? What are three or four things that we ought to be thinking about putting in place right this moment?

Rosemary Gibson: [26:42](#) Bill, one of the recommendations I made last summer to the US-China Economic and Security Review Commission, just to get things going, is to have where Congress has authority. Have the Department of Defense, the VA, and the Health and Human Services Department, we have an \$8 billion strategic national stockpile that includes critical drugs, that we use the procurement dollars now that we spend to buy medicines made here in the United States at least to start it for critical drugs. People say, there's a list of 20 critical drugs. Everybody wants to know what they are. I have an idea of what they are. I don't have the official list, but it's pretty obvious. This is bread and butter stuff you need to run your healthcare system.

Rosemary Gibson: [27:29](#) And so, enable the DOD to cut through the red tape to allow the federal agencies to buy medicines and to support products made in the United States. That would be a huge step forward. You've got 10 million people covered by the Department of Defense, another 10 million in the VA, 20 million people. Just get those contracts going. It's one thing to have manufacturing here, but you need people to buy them.

Bill Walton: [27:55](#) Well, it seems to me that as you point out in your book that disclosure would be an incredibly powerful tool because right now if you look at your label of pills, your bottle of pills and you look at the label, you can't see where it's manufactured. You can see maybe who distributes it, but you don't know its country of origin. And particularly if it's a sub-ingredient that comes from China, you're not going to see that in the label, ever. Yet, as you point out, something like 95% of Americans do not trust drugs that are manufactured in China. So a simple disclosure on the bottles, I think would create an incredible consumer demand to say, "Look, we want you to pull that manufacturing back here and bring those jobs back to Connecticut and Illinois and all the places where they've been lost." Thoughts?

- Rosemary Gibson: [28:46](#) Well, it's timely you say that because a special interest got together and there was a federal circuit court case in DC that determined, it was around the VA, the VA has a provision under the Trade Agreements Act that they could only buy from certain designated countries. And that pertained to the core, what they call active ingredient. That's what makes a medicine, medicine. And under that Trade Agreements Act, the federal government would have to buy only from designated countries. It could not buy from China-
- Bill Walton: [29:20](#) But, we need to get the pharmaceutical-
- Rosemary Gibson: [29:22](#) ... if the API was made there. And guess what that court decision just did? It reversed that. It said if the API is made in China, but if the drug is finished, turned into a pill or a vial here in the United States, it can still be labeled as made in the United States.
- Bill Walton: [29:41](#) Well, see that's got to change.
- Frank Gaffney: [29:45](#) It's absolutely scandalous.
- Rosemary Gibson: [29:45](#) So I think they knew what was coming, and so it's, again, hiding. And so, it enables the VA, requires the VA in February 2020 to become even more dependent on China. In fact, what's really remarkable, Bill and Frank, Dr. Navarro has been talking about an executive order to have the DOD, VA, and HHS buy critical drugs made in the United States, at least to get that manufacturing capability going. It's quite remarkable, someone sent me and I saw it in the media, a draft letter to the White House opposing buy American for the military and the VA, saying it would destabilize the medicine supply chain.
- Frank Gaffney: [30:38](#) If I could just add-
- Rosemary Gibson: [30:39](#) This is just two weeks after. We have special interests that want the United States to become even more dependent on a country that has threatened to kill us by withholding medicines.
- Bill Walton: [30:48](#) Are these the pharmaceutical companies? Is this the drug lobby?
- Rosemary Gibson: [30:51](#) I'll just say they're special interests and there's a lot of them.
- Frank Gaffney: [30:54](#) Yeah. I'll say that there's pharmaceutical companies that have benefited from this arrangement. Rosemary's more diplomatic about it for her own reasons. But let me just tell you, Bill, I think

that what we're watching here is symptomatic of, well, divided loyalties is how I would put it. They're more loyal to the profit opportunities than they are to the American people. And we've just seen how President Trump has, I think, quite properly treated 3M over this decision that it was going to sell masks that Americans need to the Chinese or others overseas. And, he didn't take it well. As he said, he was going to get even uglier over this sort of thing, and I think everyone should be on notice that this is a matter of national security as well as public health. And if we treat it that way, the businesses usual arrangements that have gotten us in this fix, as Rosemary's done such a brilliant job documenting, are not tolerable any longer. It must be ended.

Bill Walton: [32:10](#) Well, for a long time, and I'm not going to go to the mattress defending drug companies, but for a long time everybody thought, well, let's make this stuff where it's cheapest, it's good for the consumer, it brings China in, and that's a win-win for everybody. But particularly when President Trump came in and started challenging China exposing all these, I think one of the big thing he exposed is just the overall strategic intentions that China has. And so we've been negotiating these economic arrangements as if we're just all free traders and they're not, they never were, and never will be.

Frank Gaffney: [32:50](#) But they are perfectly capable of taking advantage of that asymmetry. And I think they must be pinching themselves that they've gotten away with it for as long as they have. And if there's any silver lining, and it's hard to say there can be in pandemic where tens of thousands of Americans are losing their lives and many more may yet. But if there is any upside to what's happened here, it is that Rosemary Gibson is being given the kind of hearing she should have gotten two years ago. And more to the point, President Trump himself and those of us who've been arguing for a decoupling from the kind of business as usual arrangements that you described, that at a point may have been perfectly reasonable or innocuous, not anymore. It's not tolerable anymore.

Bill Walton: [33:47](#) Rosemary?

Rosemary Gibson: [33:49](#) Well, when I'm out talking with people of all political stripes on social media, the public is outraged. You can't tell the difference between people who are Democrats or Republicans in the audience because everybody takes a pill or they give something to their child or grandchild.

- Frank Gaffney: [34:10](#) Or grandparent.
- Rosemary Gibson: [34:12](#) And it's a matter of trust.
- Frank Gaffney: [34:17](#) What's interesting, Bill, if I could just on that point, we, as you know, as a member of the Committee on the Present Danger: China as Rosemary Gibson is, we did a poll, a national poll before this pandemic really set in which bears out exactly what Rosemary just said. Even then, not just at the top-line level, but the demographic subgroups of that poll of a thousand likely voters in the 2020 election overwhelmingly and uniformly were deeply concerned about China and very uneasy about the idea that anybody would be recommending more of the business as usual that's gotten this in our present parlous fix with them.
- Rosemary Gibson: [35:00](#) Bill, as your viewers may want to know updates on this and to create more momentum and awareness, people can follow me on Twitter at Rosemary 100. It's a very extraordinary dialogue that goes on there with new information out there and people's reactions, and we crowdsource information to know what's going on. So this is a way of creating that momentum to raise awareness and to push for a common-sense policy and practice to be able to make some of our own medicines here in the United States.
- Frank Gaffney: [35:34](#) And, also could mention to them [presentdangerchina.org](#), where a number of videos that Rosemary has done with the Committee on the Present Danger China and a lot of other very relevant information are available as well.
- Bill Walton: [35:49](#) As a board member of yours, it's outstanding information there and I think it does outline all of the issues we face coming from China. Here's what I suggest. We've sort of used our time we have today, I'm looking at your testimony and I'm looking at the whole list of recommendations, I suggest we come back with a pretty detailed list of things that people ought to be lobbying for because we've come at some pretty high-level things. But let's nail this down into some actionable items for people watching or listening because I don't think there's many more important issues right now that we address. We get past the virus, this dependence on China and China's aggression is maybe the biggest problem America faces. Good plan/.
- Rosemary Gibson: [36:40](#) Look forward to that.
- Bill Walton: [36:42](#) Okay.

- Rosemary Gibson: [36:42](#) In the meantime, Bill, China Rx is available on Kindle. We're trying to get actual books produced and online. That's coming. But the meantime, it's available on Kindle. Share it with your member of Congress, with people who you think should know, and together we can make a difference.
- Bill Walton: [37:00](#) Yeah, I would just stress that again. The reading through it on Kindle, which I did, it's the best compendium of both where we are now, where we ought to go, but also how we got here. And the human stories in this are vivid and particularly the doctor that got overdosed with heparin, which was manufactured with contaminants from China. You read that story, you think about the drugs you get completely differently.
- Rosemary Gibson: [37:33](#) Absolutely.
- Bill Walton: [37:37](#) Rosemary, give us your Twitter again.
- Rosemary Gibson: [37:40](#) Yes, it's at Rosemary 100. I hope you'll follow and sign on and contribute to the dialogue.
- Bill Walton: [37:47](#) Frank?
- Rosemary Gibson: [37:47](#) On presentdangerchina.org.
- Bill Walton: [37:51](#) Okay. Well, thanks. We'll be back with our detailed list and thanks for joining us, watching, listening. We can be found on YouTube and all the major podcast platforms. And we'll be back with this and other subjects that matter right now with the crisis America is facing. So, thanks for watching.
- Speaker 1: [38:13](#) Thanks for listening. Want more? Be sure to subscribe at [thebillwaltonshow.com](http://thebillwaltonshow.com) or on iTunes.